[{"x_label":"High-grade glioma/astrocytoma  (Dataset = PBTA, Specimen = Pediatric Primary and Relapse Tumors, N = 45)","specimen_descriptor_fill":"Pediatric Primary Tumors","box_sample_count":29,"Gene_Ensembl_ID":"ENSG00000213420","Gene_symbol":"GPC2","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"PBTA","Disease":"High-grade glioma/astrocytoma","GTEx_tissue_subgroup":"","EFO":"MONDO_0016680","MONDO":"MONDO_0016680","GTEx_tissue_subgroup_UBERON":"","TPM_mean":8.1,"TPM_sd":12.86,"TPM_min":0.16,"TPM_25th_percentile":1.63,"TPM_median":3.58,"TPM_75th_percentile":7.29,"TPM_max":53.73},{"x_label":"High-grade glioma/astrocytoma  (Dataset = PBTA, Specimen = Pediatric Primary and Relapse Tumors, N = 45)","specimen_descriptor_fill":"Pediatric Relapse Tumors","box_sample_count":16,"Gene_Ensembl_ID":"ENSG00000213420","Gene_symbol":"GPC2","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"PBTA","Disease":"High-grade glioma/astrocytoma","GTEx_tissue_subgroup":"","EFO":"MONDO_0016680","MONDO":"MONDO_0016680","GTEx_tissue_subgroup_UBERON":"","TPM_mean":13.76,"TPM_sd":32.77,"TPM_min":0.34,"TPM_25th_percentile":0.86,"TPM_median":4.44,"TPM_75th_percentile":7.02,"TPM_max":133.7},{"x_label":"Glioblastoma Multiforme  (Dataset = TCGA, Specimen = TCGA Primary and Relapse Tumors, N = 165)","specimen_descriptor_fill":"TCGA Primary Tumors","box_sample_count":152,"Gene_Ensembl_ID":"ENSG00000213420","Gene_symbol":"GPC2","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"TCGA","Disease":"Glioblastoma Multiforme","GTEx_tissue_subgroup":"","EFO":"EFO_0000519","MONDO":"MONDO_0018177","GTEx_tissue_subgroup_UBERON":"","TPM_mean":20.95,"TPM_sd":26.04,"TPM_min":0.75,"TPM_25th_percentile":5.63,"TPM_median":11.36,"TPM_75th_percentile":25.61,"TPM_max":171.81},{"x_label":"Glioblastoma Multiforme  (Dataset = TCGA, Specimen = TCGA Primary and Relapse Tumors, N = 165)","specimen_descriptor_fill":"TCGA Relapse Tumors","box_sample_count":13,"Gene_Ensembl_ID":"ENSG00000213420","Gene_symbol":"GPC2","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"TCGA","Disease":"Glioblastoma Multiforme","GTEx_tissue_subgroup":"","EFO":"EFO_0000519","MONDO":"MONDO_0018177","GTEx_tissue_subgroup_UBERON":"","TPM_mean":13.75,"TPM_sd":19.3,"TPM_min":1.2,"TPM_25th_percentile":2.4,"TPM_median":4.01,"TPM_75th_percentile":17.67,"TPM_max":69.9},{"x_label":"Low-grade glioma  (Dataset = TCGA, Specimen = TCGA Primary and Relapse Tumors, N = 521)","specimen_descriptor_fill":"TCGA Primary Tumors","box_sample_count":507,"Gene_Ensembl_ID":"ENSG00000213420","Gene_symbol":"GPC2","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"TCGA","Disease":"Low-grade glioma","GTEx_tissue_subgroup":"","EFO":"MONDO_0021637","MONDO":"MONDO_0021637","GTEx_tissue_subgroup_UBERON":"","TPM_mean":19.05,"TPM_sd":15.62,"TPM_min":0.97,"TPM_25th_percentile":9.16,"TPM_median":15.43,"TPM_75th_percentile":24.85,"TPM_max":123.38},{"x_label":"Low-grade glioma  (Dataset = TCGA, Specimen = TCGA Primary and Relapse Tumors, N = 521)","specimen_descriptor_fill":"TCGA Relapse Tumors","box_sample_count":14,"Gene_Ensembl_ID":"ENSG00000213420","Gene_symbol":"GPC2","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"TCGA","Disease":"Low-grade glioma","GTEx_tissue_subgroup":"","EFO":"MONDO_0021637","MONDO":"MONDO_0021637","GTEx_tissue_subgroup_UBERON":"","TPM_mean":26.71,"TPM_sd":16.68,"TPM_min":4.4,"TPM_25th_percentile":13.83,"TPM_median":27.83,"TPM_75th_percentile":33.23,"TPM_max":58.78},{"x_label":"Ovarian Serous Cystadenocarcinoma  (Dataset = TCGA, Specimen = TCGA Primary and Relapse Tumors, N = 378)","specimen_descriptor_fill":"TCGA Primary Tumors","box_sample_count":373,"Gene_Ensembl_ID":"ENSG00000213420","Gene_symbol":"GPC2","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"TCGA","Disease":"Ovarian Serous Cystadenocarcinoma","GTEx_tissue_subgroup":"","EFO":"EFO_1000043","MONDO":"MONDO_0006046","GTEx_tissue_subgroup_UBERON":"","TPM_mean":3.07,"TPM_sd":4.6,"TPM_min":0.11,"TPM_25th_percentile":0.8,"TPM_median":1.6,"TPM_75th_percentile":3.31,"TPM_max":44.87},{"x_label":"Ovarian Serous Cystadenocarcinoma  (Dataset = TCGA, Specimen = TCGA Primary and Relapse Tumors, N = 378)","specimen_descriptor_fill":"TCGA Relapse Tumors","box_sample_count":5,"Gene_Ensembl_ID":"ENSG00000213420","Gene_symbol":"GPC2","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"TCGA","Disease":"Ovarian Serous Cystadenocarcinoma","GTEx_tissue_subgroup":"","EFO":"EFO_1000043","MONDO":"MONDO_0006046","GTEx_tissue_subgroup_UBERON":"","TPM_mean":2.07,"TPM_sd":2.47,"TPM_min":0.08,"TPM_25th_percentile":0.37,"TPM_median":1.25,"TPM_75th_percentile":2.47,"TPM_max":6.16},{"x_label":"Sarcoma  (Dataset = TCGA, Specimen = TCGA Primary and Relapse Tumors, N = 261)","specimen_descriptor_fill":"TCGA Primary Tumors","box_sample_count":258,"Gene_Ensembl_ID":"ENSG00000213420","Gene_symbol":"GPC2","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"TCGA","Disease":"Sarcoma","GTEx_tissue_subgroup":"","EFO":"EFO_0000691","MONDO":"MONDO_0005089","GTEx_tissue_subgroup_UBERON":"","TPM_mean":4.86,"TPM_sd":6.28,"TPM_min":0.15,"TPM_25th_percentile":1.35,"TPM_median":2.63,"TPM_75th_percentile":5.95,"TPM_max":51.12},{"x_label":"Sarcoma  (Dataset = TCGA, Specimen = TCGA Primary and Relapse Tumors, N = 261)","specimen_descriptor_fill":"TCGA Relapse Tumors","box_sample_count":3,"Gene_Ensembl_ID":"ENSG00000213420","Gene_symbol":"GPC2","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"TCGA","Disease":"Sarcoma","GTEx_tissue_subgroup":"","EFO":"EFO_0000691","MONDO":"MONDO_0005089","GTEx_tissue_subgroup_UBERON":"","TPM_mean":1.74,"TPM_sd":1.13,"TPM_min":1.02,"TPM_25th_percentile":1.08,"TPM_median":1.15,"TPM_75th_percentile":2.09,"TPM_max":3.04}]